Connections Charles River Laboratories International, Inc.

Equities

CRL

US1598641074

Biotechnology & Medical Research

Market Closed - Nyse 21:00:02 17/01/2025 GMT 5-day change 1st Jan Change
163.50 USD -1.39% Intraday chart for Charles River Laboratories International, Inc. -14.01% -11.43%

27

Listed companies

11

Private companies

80

Insiders

Relation chart of related listed companies: Charles River Laboratories International, Inc.

Active Relations

Past Relations

Relationship chart for related private companies: Charles River Laboratories International, Inc.

Active Relations

Past Relations

Related private companies: Charles River Laboratories International, Inc.

Charles River Laboratories Holdings Ltd.

Financial Conglomerates

Charles River Discovery Research Services UK Ltd.

Miscellaneous Commercial Services

BioFocus DPI (Holdings) Ltd.

Financial Conglomerates

Charles River Laboratories Edinburgh Ltd.

Pharmaceuticals: Major

Charles River Discovery Research Services Finland Oy

Miscellaneous Commercial Services

Charles River UK Ltd.

Miscellaneous Commercial Services

Argenta Discovery 2009 Ltd.

Miscellaneous Commercial Services

American Academy of Arts & Sciences

Miscellaneous Commercial Services

National Academy of Medicine (United States)

Miscellaneous Commercial Services

National Academy of Sciences

Miscellaneous Commercial Services

Active Relations

Past Relations

Connection statistics

Active

Inactive

Listed companies

Private companies

Activities of related companies

Miscellaneous Commercial Services10
Pharmaceuticals: Major7
Biotechnology5
Medical Specialties4
Financial Conglomerates2
Packaged Software2
Industrial Machinery2
Medical/Nursing Services1
Aerospace & Defense1
Oil & Gas Production1

Countries of related companies

United States24
United Kingdom8
Belgium1
Finland1
Luxembourg1
Australia1
Switzerland1
Denmark1
Logo Charles River Laboratories International, Inc.
Charles River Laboratories International, Inc. specializes in the development of products and services in the field of research and non-clinical drug development for pharmaceutical companies, government agencies and academic institutions. Net sales break down by activity as follows: - discovery and safety assessment services (63.4%): discovery services for the identification, screening and selection of main compounds for the development of new drug candidates, and in vivo and in vitro testing, including pharmacokinetic, bioanalytical, metabolic, toxicological and pathological studies, for the safety assessment of pharmaceutical products, medical devices, animal health products, chemical and agrochemical products and biocides; - development and sale of research models and related services (19.2%): mice, rats, immunodeficient models, rabbits, guinea pigs, hamsters, etc. The group also offers primary cells and specialized products (bioconservation products, freezing media for cell cultures, antigens, peptides, humanized mouse models, etc.) for the development and manufacture of new cell therapies ; - development of solutions used in drug manufacturing processes (17.5%): products and services for microbiological testing, in vitro testing, endotoxin testing, microbial identification, development, manufacturing of avian vaccines, etc. The group also offers contract manufacturing services for cell and gene therapies. Net sales break down by source of income between sales of services (83.3%) and sales of products (16.7%). Net sales are distributed geographically as follows: the United States (56.8%), Europe (26%), Canada (11.8%), Asia/Pacific (4.9%) and other (0.4%).
Employees
21,100
More about the company